Emerging Therapies in Severe Eosinophilic Asthma

被引：1
作者：
Pang, Pee Hwee [1 ]
Brightling, Christopher E. [2 ,3 ]
机构：
[1] Tan Tock Seng Hosp, Dept Resp & Crit Care Med, Singapore, Singapore
[2] Univ Leicester, Dept Infect Immun & Inflammat, NIHR Resp Biomed Res Unit, Inst Lung Hlth, Leicester, Leics, England
[3] Univ Hosp Leicester NHS Trust, Leicester, Leics, England
来源：
ARCHIVOS DE BRONCONEUMOLOGIA | 2017年 / 53卷 / 05期
关键词：
DOUBLE-BLIND; INHALED CORTICOSTEROIDS; MEPOLIZUMAB; EFFICACY; PHASE-3; SAFETY; BENRALIZUMAB; MULTICENTER;
D O I：
10.1016/j.arbres.2017.01.012
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页码：233 / 234
页数：2
相关论文
共 50 条
[31]   Efficacy and safety of mepolizumab in a real-world cohort of patients with severe eosinophilic asthma [J].
Pertzov, Barak ;
Avraham, Unterman ;
Osnat, Shtraichman ;
Dorit, Shitenberg ;
Dror, Rosengarten ;
Reuven, Kramer Mordechai .
JOURNAL OF ASTHMA, 2021, 58 (01) :79-84
[32]   Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility [J].
Humbert, Marc ;
Albers, Frank C. ;
Bratton, Daniel J. ;
Yancey, Steven W. ;
Liu, Mark C. ;
Hozawa, Soichiro ;
Llanos, Jean-Pierre ;
Kwon, Namhee .
RESPIRATORY MEDICINE, 2019, 154 :69-75
[33]   Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype [J].
Jackson, David J. ;
Wechsler, Michael E. ;
Jackson, Daniel J. ;
Bernstein, David ;
Korn, Stephanie ;
Pfeffer, Paul E. ;
Chen, Ruchong ;
Saito, Junpei ;
de Luiz Martinez, Gustavo ;
Dymek, Lucyna ;
Jacques, Loretta ;
Bird, Nicholas ;
Schalkwijk, Stein ;
Smith, Douglas ;
Howarth, Peter ;
Pavord, Ian D. .
NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (24) :2337-2349
[34]   Twice-Yearly Depemokimab in Severe Asthma with an Eosinophilic Phenotype [J].
Jackson, David J. ;
Wechsler, Michael E. ;
Jackson, Daniel J. ;
Bernstein, David ;
Korn, Stephanie ;
Pfeffer, Paul E. ;
Chen, Ruchong ;
Saito, Junpei ;
Martinez, Gustavo de Luiz ;
Dymek, Lucyna ;
Jacques, Loretta ;
Bird, Nicholas ;
Schalkwijk, Stein ;
Smith, Douglas ;
Howarth, Peter ;
Pavord, Ian D. .
NEW ENGLAND JOURNAL OF MEDICINE, 2024,
[35]   Treatment of severe, uncontrolled eosinophilic asthma: Where we are heading [J].
Bernstein, Jonathan A. ;
Panettieri, Reynold, Jr. .
JOURNAL OF ASTHMA, 2019, 56 (05) :459-472
[36]   Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma [J].
Yancey, Steven W. ;
Ortega, Hector G. ;
Keene, Oliver N. ;
Bradford, Eric S. .
ALLERGY ASTHMA AND CLINICAL IMMUNOLOGY, 2019, 15 (01)
[37]   Cost-effectiveness analysis of anti-IL-5 therapies of severe eosinophilic asthma in Spain [J].
Gonzalez-Barcala, Francisco Javier ;
Munoz-Gall, Xavier ;
Mariscal, Esther ;
Garcia, Andrea ;
Yang, Shibing ;
van de Wetering, Gijs ;
Izquierdo-Alonso, Jose Luis .
JOURNAL OF MEDICAL ECONOMICS, 2021, 24 (01) :874-882
[38]   Biological therapies targeting the type 2 inflammatory pathway in severe asthma (Review) [J].
Fildan, Ariadna Petronela ;
Rajnoveanu, Ruxandra-Mioara ;
Cirjaliu, Roxana ;
Pohrib, Ionela ;
Tudorache, Emanuela ;
Ilie, Adrian Cosmin ;
Oancea, Cristian ;
Tofolean, Doina .
EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2021, 22 (05)
[39]   Comparison of Monoclonal Antibodies for Treatment of Uncontrolled Eosinophilic Asthma [J].
Koski, Renee R. ;
Grzegorczyk, Kirsten M. .
JOURNAL OF PHARMACY PRACTICE, 2020, 33 (04) :513-522
[40]   Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab [J].
Pelaia, Corrado ;
Vatrella, Alessandro ;
Busceti, Maria Teresa ;
Gallelli, Luca ;
Terracciano, Rosa ;
Savino, Rocco ;
Pelaia, Girolamo .
DRUG DESIGN DEVELOPMENT AND THERAPY, 2017, 11 :3137-3144
12345